ANDA 206144, held by Chartwell Rx. Cefixime.
As of Nov 13, 2026, ANDA 206144 (Cefixime), held by Chartwell Rx, was first approved by FDA on Nov 17, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
